Ken Griffin Catalyst Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$15.19 - $21.35 $133,672 - $187,880	8,800 Added 133.33%	15,400 $306,000
Q2 2024 Aug 14, 2024	SELL	$14.68 - $16.92 $889,608 - $1.03 Million	-60,600 Reduced 90.18%	6,600 $102,000
Q1 2024 May 15, 2024	BUY	$13.18 - $17.11 $608,916 - $790,482	46,200 Added 220.0%	67,200 $1.07 Million
Q4 2023 Feb 14, 2024	SELL	$11.78 - $17.29 $226,176 - $331,968	-19,200 Reduced 47.76%	21,000 $353,000
Q3 2023 Nov 14, 2023	BUY	$11.69 - $15.02 $90,013 - $115,654	7,700 Added 23.69%	40,200 $469,000
Q2 2023 Aug 14, 2023	BUY	$11.5 - $18.08 $70,150 - $110,287	6,100 Added 23.11%	32,500 $436,000
Q1 2023 May 15, 2023	SELL	$14.34 - $21.05 $355,632 - $522,040	-24,800 Reduced 48.44%	26,400 $437,000
Q4 2022 Feb 14, 2023	BUY	$12.25 - $19.5 $219,275 - $349,050	17,900 Added 53.75%	51,200 $952,000
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $100,252 - $220,384	14,200 Added 74.35%	33,300 $427,000

327

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.3B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.